A Non-severe Coronavirus Disease 2019 Patient With Persistently High Interleukin-6 Level

Hambali, Nurfarah Lydia Binti; Noh, Malehah Mohd; Paramasivam, Shahleni; Chua, Tock Hing; Hayati, Firdaus; Payus, Alvin Oliver; Tee, Tze Yuan; Rosli, Khairul Taufiq; Isnadi, Mohammad Faruq Abd Rachman; Manin, Benny Obrain

doi:10.3389/fpubh.2020.584552

Cited by 9 publications

(6 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the consensus statement of the American Association for the Study of Liver Diseases[ 46 ], it is recommended to consider etiologies outside SARS-CoV-2, such as other viral hepatitis. This has been proven in a case reported by Hambali et al [ 47 ], where a patient with SARS-CoV-2 infection presented with abnormal liver function and high IL-6, which was due to hepatocellular carcinoma. It is also essential to consider other indirect causes of liver injury such as myositis, cardiac injury, ischemia, and cytokine release syndrome.…”

Section: Current Management Of Sars-cov-2-induced Liver Injury In Var...mentioning

confidence: 81%

SARS-CoV-2-induced liver injury: A review article on the high-risk populations, manifestations, mechanisms, pathological changes, management, and outcomes

Payus¹,

Noh²,

Azizan³

et al. 2022

World J Gastroenterol

Self Cite

View full text Add to dashboard Cite

The novel coronavirus disease 2019 is an infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and was declared a global pandemic with more than 500 million reported cases and more than 6 million deaths worldwide to date. Although it has transitioned into the endemic phase in many countries, the mortality rate and overall prognosis of the disease are still abysmal and need further improvement. There has been evidence that shows the significance of SARS-CoV-2-related liver injury. Here, we review the literature on the various spectrum of SARS-CoV-2 infection-induced liver injury and the possible mechanisms of damage to the hepatobiliary system. This review aimed to illustrate the latest understanding regarding SARS-CoV-2-induced liver injury including the high-risk populations, the characteristic clinical manifestations, the possible pathogenic mechanism, the pathological changes, the current suggestions for clinical treatment for various spectrum of populations, and the prognosis of the condition. In conclusion, SARS-CoV-2 patients with a liver injury warrant close monitoring as it is associated with the more severe and poorer outcome of the infection.

show abstract

Section: Current Management Of Sars-cov-2-induced Liver Injury In Var...mentioning

confidence: 81%

SARS-CoV-2-induced liver injury: A review article on the high-risk populations, manifestations, mechanisms, pathological changes, management, and outcomes

Payus¹,

Noh²,

Azizan³

et al. 2022

World J Gastroenterol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Overall, 641 articles were screened, 21 of which were selected according to the above mentioned criteria 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 . The included articles were all case reports (except for one case series [10] ), and contained description of 21 cases.…”

Section: Resultsmentioning

confidence: 99%

Acute splanchnic vein thrombosis in patients with COVID-19: A systematic review

Buso¹,

Becchetti²,

Berzigotti³

2021

Digestive and Liver Disease

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…Most of the asymptomatic/mild-form patients had elevated IL-6 concentrations. Hambali et al (2020) also described a non-severe COVID-19 patient with persistently high IL-6 level [ 43 ]. Our patients with moderate, severe, and critical forms of disease had higher concentrations of IL-6.…”

Section: Discussionmentioning

confidence: 99%

The Immune, Inflammatory and Hematological Response in COVID-19 Patients, According to the Severity of the Disease

et al. 2023

View full text Add to dashboard Cite

Introduction: The aim of this study was to evaluate the immune and inflammatory responses in COVID-19 patients by dosing specific IgM and IgG total antibodies and interleukin 6, correlating them with the hematological and biochemical blood parameters and comparing them by the form of the disease. Materials and methods: One hundred twenty-five patients with polymerase chain reaction-confirmed COVID-19, hospitalized between 15.03.2020 and 1.07.2020 in the Clinical Hospital of Infectious Diseases “Sf. Parascheva” Iaşi, were tested by chemiluminescence for the presence of anti-SARS-CoV-2 IgM and IgG and IL-6 in the serum. The results were correlated with the results of the CBC count and serum biochemical parameters detected on the admission day. The patients presented different forms of the disease (asymptomatic, mild, moderate, severe, and critical) according to World Health Organization (WHO) criteria for the clinical management of COVID-19. Results: The amplitude of the immune response was directly correlated with the form of the disease. In the asymptomatic/mild form patients, the IL-6 and CRP concentrations were significantly higher and eosinophil count was significantly lower compared with the reference interval. In the moderate form, the concentrations of IL-6, CRP, and IgG were significantly higher, compared with the reference interval, while eosinophil count and eGFR were significantly lower. In severe/critical COVID-19 patients, IL-6, CRP, NLR, PLR, glucose, AST, urea, creatinine, and eGFR were significantly higher compared with the reference interval, while eosinophil count was significantly lower. IL-6 boosted in all forms of COVID-19, with a major increase in severe and critical patients. IL-6, neutrophil count, % neutrophils, NLR, PLR, CRP, AST, and urea increased with the severity of the SARS-CoV-2 infection, and the lymphocyte count, % lymphocytes, eosinophil count, % eosinophils, and hemoglobin decreased with the increased severity of COVID-19. Conclusions: The amplitude and the moment of appearance of the immune response depended on the form of the disease. IgM generally occurred in the first 14 days of illness, and IgG appeared beginning with the second week of disease. IgG titer increased rapidly until the fourth week of disease and decreased slowly after 4 weeks. The amplitudes of all the tested inflammatory and serological markers depended on the COVID-19 form, increasing somewhat in the moderate forms and even more in the critical ones. The lymphocyte and eosinophil count are able to predict the risk of severe COVID-19.

show abstract

A Non-severe Coronavirus Disease 2019 Patient With Persistently High Interleukin-6 Level

Cited by 9 publications

References 9 publications

SARS-CoV-2-induced liver injury: A review article on the high-risk populations, manifestations, mechanisms, pathological changes, management, and outcomes

SARS-CoV-2-induced liver injury: A review article on the high-risk populations, manifestations, mechanisms, pathological changes, management, and outcomes

Acute splanchnic vein thrombosis in patients with COVID-19: A systematic review

The Immune, Inflammatory and Hematological Response in COVID-19 Patients, According to the Severity of the Disease

Contact Info

Product

Resources

About